In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Ceribell, Inc., with a price target of $29.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
William Plovanic has given his Buy rating due to a combination of factors surrounding Ceribell, Inc.’s innovative technology and recent achievements. The company’s technology, particularly its Neonate technology, has generated significant interest among clinicians, as it addresses the critical need for better diagnostic and treatment pathways for epilepsy, especially in neonates and pediatric patients.
Ceribell’s recent FDA 510(k) clearance for its Clarity for Neonates further strengthens its position in the market. The technology’s high accuracy rates in seizure detection, as demonstrated in clinical studies, highlight its potential for widespread adoption. Additionally, the company’s efforts to tailor the technology specifically for neonates, with redesigned hardware that is sensitive to their needs, underscore its commitment to addressing this challenging patient population. These factors collectively contribute to Plovanic’s confidence in Ceribell’s growth prospects and the Buy rating.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $30.00 price target.